Traditionally, a blood test for prostate specific antigen (PSA) is used for initial screening. But PSA can be misleading and lead to unnecessary biopsies for slow-growing cancers. MPS2 addresses this problem by analyzing 18 genes associated with high-grade prostate cancer.
In studies using urine and tissue samples, MPS2 successfully detected cancers with a high risk of spreading. “Our standard tests cannot accurately identify patients with severe cancer,” explains study co-author John Wei. “MPS2 helps us identify these high-risk cases, allowing us to prioritize those who truly need treatment.”
MPS2 is currently available through LynxDx, a company created by the University of Michigan.
News materials cannot be equated with a doctor’s prescription. Consult an expert before making a decision.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
